Status:
UNKNOWN
B2RAD Translational Medicine Study
Lead Sponsor:
Sohail Rao
Conditions:
Specimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow Draw
Eligibility:
All Genders
Brief Summary
Recent advances in understanding the molecular and cellular pathology of many diseases have resulted in direct benefit to today's patients. The translational research studies that have led to these ad...
Eligibility Criteria
Inclusion
- Any subject choosing to give consent for participation will be included.
- Any subject in which the primary diagnosis of cancer was made at the DHR Health System.
Exclusion
- Any subject deemed unable to provide legally effective consent.
- Any pediatric subject where the subject does not freely give his or her assent or where his or her parent/guardian does not give consent.
Key Trial Info
Start Date :
January 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05292430
Start Date
January 22 2020
End Date
December 1 2022
Last Update
March 23 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
DHR Health Institute for Research and Development
Edinburg, Texas, United States, 78539
2
DHR Health
Edinburg, Texas, United States, 78539